The fact that genetic ablation of SORT1 restores and normalizes PGRN levels in brain uniquely positions the SORT1–PGRN axis as an ideal target for PGRN-based therapy in FTD-GRN (19). This evidence concerns the gene SORT1 and frontotemporal dementia.